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ABSTRACT
Background and objectives Chronic widespread pain
(CWP) is a common disorder affecting ∼10% of the
general population and has an estimated heritability of
48–52%. In the ﬁrst large-scale genome-wide association
study (GWAS) meta-analysis, we aimed to identify
common genetic variants associated with CWP.
Methods We conducted a GWAS meta-analysis in
1308 female CWP cases and 5791 controls of European
descent, and replicated the effects of the genetic
variants with suggestive evidence for association in 1480
CWP cases and 7989 controls. Subsequently, we studied
gene expression levels of the nearest genes in two
chronic inﬂammatory pain mouse models, and examined
92 genetic variants previously described associated with
pain.
Results The minor C-allele of rs13361160 on
chromosome 5p15.2, located upstream of chaperonin-
containing-TCP1-complex-5 gene (CCT5) and downstream
of FAM173B, was found to be associated with a 30%
higher risk of CWP (minor allele frequency=43%;
OR=1.30, 95% CI 1.19 to 1.42, p=1.2×10−8).
Combined with the replication, we observed a slightly
attenuated OR of 1.17 (95% CI 1.10 to 1.24,
p=4.7×10−7) with moderate heterogeneity (I2=28.4%).
However, in a sensitivity analysis that only allowed
studies with joint-speciﬁc pain, the combined association
was genome-wide signiﬁcant (OR=1.23, 95% CI 1.14 to
1.32, p=3.4×10−8, I2=0%). Expression levels of Cct5
and Fam173b in mice with inﬂammatory pain were higher
in the lumbar spinal cord, not in the lumbar dorsal root
ganglions, compared to mice without pain. None of the
92 genetic variants previously described were
signiﬁcantly associated with pain (p>7.7×10−4).
Conclusions We identiﬁed a common genetic variant
on chromosome 5p15.2 associated with joint-speciﬁc
CWP in humans. This work suggests that CCT5 and
FAM173B are promising targets in the regulation of pain.
INTRODUCTION
Chronic widespread pain (CWP) is a common dis-
order, affecting about 10% of the general popula-
tion.1 The prevalence of CWP increases with age for
both men and women, but is more common in
women at any age.1 CWP represents a major under-
estimated health problem and is associated with
substantial impairment and a reduced quality of life.
It has been related to a number of physical and
affective symptoms such as fatigue, psychological
distress and somatic symptoms.1 2 Chronic muscu-
loskeletal pain is one of the most common condi-
tions seen in rheumatology clinics and accounts
for 6.2% of the total healthcare costs in The
Netherlands every year.3 Further research is needed
to be able to understand the causal mechanisms and
optimal treatment for CWP patients.
CWP causally relates to an initial local pain stimu-
lus, such as an acute injury or athletic injuries, or
another pain state such as low back pain or local
pain due to osteoarthritis (OA) or rheumatic arthritis
(RA).4–6 However, most injured subjects do not
develop CWP, and only a proportion of patients with
OA or RA develop CWP. We therefore hypothesise
that several discrete stimuli may initiate CWP via a
common ﬁnal pathway that involves the generation
of a central pain state through the sensitisation of
second order spinal neurons.
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CWP is a complex trait since both environmental and
genetic factors play a role in the aetiology. Heritability esti-
mates of twin studies suggest that 48–52% of the variance in
CWP occurrence is due to genetic factors, implying a strong
genetic component.7 A number of studies have examined
genetic variants for CWP. These candidate gene studies exam-
ined polymorphisms in genes involved in both the peripheral
and the central nervous system.8 In particular, genes involved
in neurotransmission (pathway of dopamine and serotonin9–
19), and genes important for the hypothalamic–pituitary–
adrenal axis have been considered.20 A number of genetic var-
iants in these candidate genes were found to be associated with
CWP, individual pain sites or experimental pain. However, no
consistent signiﬁcant associations have been demonstrated.
The most studied gene in relation to pain is catechol-
O-methyltransferase (COMT), an enzyme that degrades neuro-
transmitters including dopamine. The variant allele of rs4680 (or
V158M) results in reduced enzymatic activity due to its effect on
thermostability,21 and has been associated with reduced opioid
activity in response to painful stimuli resulting in increased pain
sensitivity.22 But also for COMT, no consistent results have been
observed in genetic association studies.13 23–29
Overall, the results have been conﬂicting, which is likely due
to the modest sample sizes used and paucity of replication. In
general, candidate studies are biased by previous knowledge of
the aetiology of the disease under study. Since knowledge
about the pathophysiology of CWP is poor, the chances of
success using this approach are low. Therefore our objective
was to identify genetic variants involved in CWP by means of
a large-scale hypothesis-free genome-wide association study
(GWAS) meta-analysis including 2788 cases and 13 780 con-
trols. To our knowledge, this is the ﬁrst study presenting a
large-scale GWAS meta-analysis of chronic pain. The prevalence
of CWP is approximately two times higher in women than in
men and there is strong evidence that women tolerate less
thermal and pressure pain than men.30 Therefore only women
were included in this study to reduce heterogeneity and
thereby increase power.
MATERIALS AND METHODS
We performed a meta-analysis (stage 1) of GWAS data of 1308
female Caucasian CWP cases and 5791 female Caucasian con-
trols, derived from ﬁve studies, and focused our follow-up
efforts on the single-nucleotide polymorphisms (SNPs) with
suggestive evidence of association (p<1×10−5) with CWP
(stage 2). The study outline is summarised in ﬁgure 1.
Phenotype
CWP was deﬁned as subjects having pain in the left side of the
body, in the right side of the body, above the waist, below the
waist, and in the axial skeleton (following the Fibromyalgia
Criteria of the American College of Rheumatology2). Controls
were deﬁned as subjects not having CWP. Subjects using
analgesics (ATC code: N0231) were excluded from the control
group. Detailed descriptions of the study speciﬁc inclusion cri-
teria are presented in supplementary table S1.
Study design summary
We combined the summary statistics of GWAS in a
meta-analysis comprising 1308 CWP female Caucasian cases
and 5791 female Caucasian controls (stage 1). We focused our
follow-up efforts on the SNPs with suggestive evidence of asso-
ciation (p<1×10−5) with CWP in 1480 CWP cases and 7989
controls available for replication (stage 2).
Subjects
A full detailed description of all study cohorts is presented in
table 1 and in the supplementary methods section. For the stage 1
analysis, we included studies from The Netherlands (the Erasmus
Rucphen Family study (ERF study),32 Rotterdam Study I, II and
III (RS-I, RS-II and RS-III)33), and the UK (TwinsUK34 35). All
studies were approved by their institutional ethics review commit-
tees and all participants provided written informed consent.
For our stage 2 analysis, we sought follow-up samples with
pre-existing GWAS in silico data (stage 2a) as well as de novo
genotyping (stage 2b). The studies are from the UK (the British
1958 Birth Cohort (1958BC),23 36–38 the Chingford Study
(CHINGFORD),39 40 the Dyne Steel DNA Bank for Aging and
Cognition (DSDBAC),41 the EPIdemiological study of FUNctional
Disorders (EPIFUND),20 and the Hertfordshire Cohort Study
(HCS)42); from Iceland (the Age, Gene/Environment
Susceptibility Study (AGES)43); from the USA (the Framingham
Osteoarthritis Study (FOA)44); from The Netherlands (the
Genetics osteoARthritis and Progression Study (GARP)45); and
from Germany (the Study of Health In Pomerania (SHIP)46 47). All
Figure 1 Study outline. CWP, chronic widespread pain; GWAS,
genome-wide association study.
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studies were approved by the local ethics committees and all parti-
cipants provided written informed consent.
Genotyping, quality control and imputation
Genotyping of the stage 1 cohorts was done by Illumina
Inﬁnium HumanHap550 Beadchip (RS-I and RS-II), the
Illumina Inﬁnium HumanHap610 (RS-II, RS-III, and
TwinsUK), or the Illumina Inﬁnium HumanHap300 (ERF and
TwinsUK). More details about the genotyping, quality control
(QC), and imputation are shown in the supplementary
methods section. Complete information on genotyping proto-
cols and QC measures for all stage 1 cohorts is described in the
supplementary material (see supplementary table S2). Detailed
descriptions of the QC and imputation procedures are provided
in the supplementary material (see supplementary table S3).
Genotypes of the stage 2a studies (1958BC, AGES, DSDBAC,
FOA, GARP and SHIP) were obtained from SNP arrays and
imputed data. Where unavailable, proxy SNPs were selected
based on high linkage disequilibrium (LD). The stage 2b studies
(CHINGFORD, EPIFUND and HCS) performed de novo geno-
typing, using both Sequenom iPLEX and TaqMan-based assays
(supplementary methods). Genotyping platforms, calling algo-
rithms, quality control before imputation, imputation methods
and analysis software used were all study-speciﬁc (see
supplementary tables S4 and S5). The explicit number of
follow-up SNPs genotyped in the different studies and whether
the original or a proxy SNP was used is summarised in
supplementary table S6.
GWAS analysis in the stage 1 studies
CWP was analysed as a binary trait (cases vs controls) using
logistic regression under an additive model with adjustment for
age and body mass index (see supplementary table S7). To
adjust for population substructure, we included the four most
important PCs as covariates in the regression analysis of RS-I,
RS-II and RS-III. These PCs were derived from a multidimen-
sional scaling analysis of identity-by-state distances, using
PLINK software.48 Detailed descriptions of the GWAS methods
are provided in supplementary table S8).
Stage 1: GWAS meta-analysis
p Values for association were combined using the Meta-Analysis
Tool for genome-wide association scans (METAL).49 The genomic
control method50 as implemented in METAL was used to correct
for any residual population stratiﬁcation or relatedness not
accounted for by the four most important PCs. A p value
<5×10−8 was considered genome-wide signiﬁcant while a p value
<1×10−5 was considered suggestive.51 Power calculations were
Table 1 Overview of all participating studies
Study (stage)
Reference
article Study design
Ethnic
origin
Country of
origin Medication Age/BMI
Mean age
(y)
No. of CWP
cases
No. of CWP
controls
Stage 1
ERF study 32 Family based cohort Caucasian The
Netherlands
Y Y 46.4 149 665
RS-I 33 Population based
cohort
Caucasian The
Netherlands
Y Y 69.4 563 1892
RS-II 33 Population based
cohort
Caucasian The
Netherlands
Y Y 67.9 110 668
RS-III 33 Population based
cohort
Caucasian The
Netherlands
Y Y 56.3 85 868
TwinsUK 34 35 Twins based cohort Caucasian UK Y Y 51.9 401 1698
Total no. of samples 59.7 1308 5791
Stage 2a
1958BC 23 36–38 Prospective birth
cohort
Caucasian UK N Y (born in
1958)
NA 315 2206
AGES 43 Population based
cohort
Caucasian Iceland Y Y 76.5 173 1204
DSDBAC 41 Population based
cohort
Caucasian UK Y Age only 80.1 81 219
FOA 44 Population based
cohort
Caucasian USA Y Y 59.3 384 814
GARP 45 Case control based Caucasian The
Netherlands
Y Y 58.5 67 925*
SHIP 46 47 Population based
cohort
Caucasian Germany Y Y 57.6 183 589
Stage 2b
CHINGFORD
39 40 Population based
cohort
Caucasian UK Y Y 56.6 48 337
EPIFUND 20 Population based
cohort
Caucasian UK N Age only 49.0 139 503
HCS 42 Population based
cohort
Caucasian UK Y Y 66.4 90 2117
Total no. of samples 1480 7989
*GARP consists of clinical and radiographically confirmed osteoarthritis case only; therefore we used 925 randomly chosen Rotterdam Study samples as controls.
Age/BMI Y, age and BMI data are available; Age only, no BMI data are available; AGES, Age, Gene/Environment Susceptibility study Reykjavik; BMI, body mass index; CWP,
chronic widespread pain; CHINGFORD, Chingford 1000 Women Study; DSDBAC, Dyne Steel DNA Bank for Ageing and Cognition; ERF study, Erasmus Rucpen Family study;
EPIFUND, EPIdemiological study of FUNctional Disorders study; HCS, Hertfordshire Cohort Study; FOA, Framingham Osteoarthritis Study; GARP, Genetics OsteoArthritis and
Progression study Leiden; Medication Y, information about medication use available; Medication N, medication use not available; RS, Rotterdam Study; SHIP, Study of Health In
Pomerania; TwinsUK, the UK Adult Twin Registry; 1958BC, 1958 Birth Cohort.
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performed using CaTS software (http://www.sph.umich.edu/csg/
abecasis/CaTS/). Using Bonferroni correction (p<5×10−8), power
calculations showed that we had approximately 80% power to
detect an OR of 1.30 for SNPs with a minor allele frequency
(MAF) of 0.43, given a disease prevalence of 10% for 1308 cases
and 5791 controls in the discovery group. Using a p value
<1×10−5, we had 80% power to detect an OR of 1.25.
SNP selection for replication
We aimed to select SNPs for replication (stage 2) that were
enriched for signals of association with CWP. All SNPs with
suggestive evidence for association in the stage 1 analyses were
selected and separated into independent loci by taking the
most signiﬁcantly associated SNP and eliminating all SNPs that
have a HapMap CEU pairwise correlation coefﬁcient r2>0.8
with that SNP using the PLINK software.
Meta-analysis of stage 1 and stage 2 results
We combined the stage 1 and stage 2 association results to
derive a combined meta-analysis for the suggestively associated
loci. METAL was used to conduct a ﬁxed-effects meta-analysis
as in stage 1. Estimated heterogeneity variance and forest plots
were generated using comprehensive meta-analysis (http://
www.meta-analysis.com).
Functional analysis of associated SNPs
To determine whether the associated SNPs have any regulatory
effect on gene expression levels, we checked their effect (and
the effect of the linked SNPs) on the expression levels of their
neighbouring genes. We used the 1000 genomes data in the
SNAP software52 53 to identify those SNPs having LD thresh-
olds of r2>0.1. We searched two publicly available eQTL data-
bases: the NCBI GTEx (Genotype-Tissue Expression) eQTL
browser (http://www.ncbi.nlm.nih.gov/gtex/GTEX2/gtex.cgi)
and the expression Quantitative Trait Loci database (http://
eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/). We used SIFT54 to
predict whether the coding non-synonymous variant causing
an amino acid substitution affects protein function.
RNA expression analyses in mice
For functional follow-up, two independent mouse models of inﬂam-
matory pain were studied. The ﬁrst model was based on carra-
geenan injections; female C57Bl/6 mice received an intraplantar
injection of 20 μl λ-carrageenan (2% (w/v), Sigma Aldrich,
Zwijndrecht, the Netherlands) in saline in both hind paws.55 The
second model was based on Complete Freund’s Adjuvant (CFA)
injections; male C57Bl/6 mice (Harlan Laboratories) received an
intraplantar injection of 20 μl CFA (Sigma-Aldrich) in saline in both
hind paws.56 Controls were injected with saline only. At day 3
(after CFA injection) or day 6 (after carrageenan injection), thermal
sensitivity (heat withdrawal latency time) was measured using the
Hargreaves (IITC Life Science, Woodland Hills, California, USA) test
as described.57 Intensity of the light beam was chosen to induce
heat withdrawal latency time of approximately 8 s at baseline.
After measurement the mice were sacriﬁced and the lumbar
(L2–L5) spinal cord and the dorsal root ganglions (DRG) (L2–
L5) were isolated. These areas of spinal cord and DRG were
selected because pain transmission from the hind paws is
mediated via primary sensory neurons that have their cell
bodies in the lumbar DRG, and transmit the signal to the
lumbar spinal cord through sensory ﬁbres in the dorsal roots.
Total RNA was isolated and mRNA levels of Cct5 and
Fam173b were measured in the spinal cord and the DRG. For
more details, see the supplementary methods section.
All experiments were performed in accordance with inter-
national guidelines and approved by the experimental animal
committee of the University Medical Center Utrecht (carra-
geenan experiment) or the UK Home Ofﬁce Animals (Scientiﬁc
Procedures) Act 1986 (CFA experiment). Mice used for the car-
rageenan experiment were bred and maintained in the animal
facility of the University of Utrecht (The Netherlands).
Systemic review of genetic variants previously described
We systematically searched for associations earlier reported with
pain in the HugeNavigator PhenoPedia database.58 We used the
search term ‘pain’ and checked all publications for genes and SNPs
associated with pain at least twice. Genes and SNPs associated
with drug therapy, facial pain, migraine and postoperative pain
were excluded. For all reported SNPs, we examined their associ-
ation with CWP in our stage 1 meta-analysis. The signiﬁcance
threshold was set at p<8×10−4 using Bonferroni correction for 65
independent genetic loci. Again, power calculations were per-
formed using CaTS software (http://www.sph.umich.edu/csg/
abecasis/CaTS/). With an α level of 8×10−4, power calculations
showed that we had approximately 80% power to detect an OR
of 1.22 for SNPs with a minor allele frequency of 20% or higher.
RESULTS
GWAS meta-analysis for CWP
The Manhattan plot and quantile–quantile plot of the initial
stage 1 meta-analysis are presented in ﬁgure 2. In total,
2 224 068 SNPs (directly genotyped or imputed) were tested for
association. The overall genomic control lambda (λGC) was
1.007, indicating no signiﬁcant population stratiﬁcation. We
identiﬁed two SNPs which were genome-wide signiﬁcant
(p<5×10−8), and another 39 SNPs with suggestive evidence
for association (p<1×10−5) located in 10 independent genomic
regions. The most signiﬁcant association was observed for two
imputed highly correlated SNPs (r2=0.97) located upstream of
the chaperonin-containing-TCP1-complex-5 gene (CCT5) and
downstream of the FAMily with sequence similarity 173,
member B gene (FAM173B) (rs13361160, p=1.2×10−8 and
rs2386592, p=2.6×10−8). For both SNPs, the minor allele
(MAF=43%) was associated with a 30% higher risk for CWP
(OR=1.30, 95% CI 1.19 to 1.42).
Meta-analysis of GWAS replication
For the 10 independent SNPs with suggestive evidence, we
pursued in silico replication data in six studies (stage 2a: 1203
CWP cases and 5032 controls) and performed de novo genotyping
in subjects from three additional studies (stage 2b: 277 CWP cases
and 2957 controls) (a detailed description of the studies is pre-
sented in table 1 and supplementary methods). The summary
results of the stage 1 and 2 meta-analysis are presented in table 2.
After combining the results of stage 1 and stage 2, the top SNP
was rs13361160 (OR=1.17, 95% CI 1.10 to 1.24, p=4.7×10−7,
I2=28.4%). Figure 3 shows a forest plot of the association of
rs13361160 with CWP across the stage 1 and stage 2 studies. The
overall effect in the replication studies (stage 2 studies) was in a
consistent direction but not signiﬁcant (OR=1.06, 95% CI 0.98 to
1.16, p=0.16). In the combined analysis, moderate heterogeneity
was observed (I2=28.4%). Supplementary table S1 shows the dif-
ferent pain assessment methods used in the different studies to
deﬁne CWP. Since four out of ﬁve stage 1 studies included
joint-speciﬁc pain only (ERF, RS-I, RS-II and RS-III), we performed
a sensitivity analysis in which stage 2 cohorts using non-joint
pain were excluded (1958BC, DSDBAC, EPIFUND, HCS and
SHIP). This resulted in a combined OR of 1.23 (95% CI 1.14 to
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1.32, p=3.4×10−8, I2= 0%). An overview of the results of the
combined meta-analysis and the separate stage 1 and stage 2 ana-
lyses is presented in table 3.
Functional analysis of rs13361160 and rs2386592
The SNPs rs13361160 and rs2386592 (r2=0.97) are annotated
to the 5p15.2-region and located 81 kb upstream of CCT5 and
57 kb downstream of FAM173B (ﬁgure 4). We tested whether
rs13361160 and rs2386592 and their linked SNPs (r2>0.1)
affected gene expression levels of CCT5 or FAM173B. In total,
we identiﬁed 130 SNPs in LD with our top SNPs, of which
two SNPs were located in the coding region: one synonymous
SNP rs1042392 in the CCT5 gene (r2=0.16, D0=0.85) and one
non-synonymous SNP rs2438652 in the FAM173B gene (r2=
0.17, D0=1.0) (see supplementary table S9). The minor allele of
rs2438652 causes a threonine-to-methionine substitution
(T75M) which is thought to be functionally neutral. SNPs
rs13361160 and rs2386592 were not recorded as inﬂuencing the
expression levels of CCT5 and FAM173B, however the linked
intronic SNP rs2445871 (r2=0.14 for both) had a direct eQTL
effect on FAM173B expression levels in liver tissue.59
RNA expression analysis in mice
We studied gene expression levels of the two nearest genes,
Cct5 and Fam173b, in the lumbar spinal cord and the DRG in
two independent mouse models of chronic inﬂammatory pain.
In both the carrageenan treated group and the CFA treated
group, mice had shorter heat withdrawal latency times than
mice injected with saline only, conﬁrming enhanced pain sensi-
tivity (p<0.001) (see supplementary ﬁgure S1).
The results from the multivariate analysis using the two
genes (Cct5 and Fam173b examined as dependent variables),
the different treatments (saline, carrageenan and CFA) and the
different tissues (DRG and spinal cord) conﬁrmed that there is
a signiﬁcant treatment effect for Cct5 (F(2,25)=3.399,
p=0.0049), as well as for Fam173b (F(2,25)=4.911, p=0.016).
Moreover, both genes showed a signiﬁcant tissue effect (Cct5:
F(1,25)=13.595, p=0.001, and Fam173b: F(1,25)=13.522,
p=0.001), as well as a signiﬁcant interaction between tissue
and treatment (Cct5: F(2,25)=6.424, p=0.006, and Fam173b:
F(1,25)=4.196, p=0.027) (ﬁgure 5). These ﬁndings indicate that
in spinal cord but not in DRG, both Fam173b and Cct5 expres-
sion levels were up-regulated in response to two different indu-
cers of inﬂammatory pain. DRG Fam173b and Cct5 expression
levels in CFA/carrageenan-treated mice were indistinguishable
from saline-treated mice.
Candidate SNPs previously associated with chronic pain
We examined whether genetic variants previously described for
association with pain were associated with CWP in our large
Figure 2 Genome-wide association results for chronic widespread pain (CWP) (stage 1). (A) Manhattan plot showing the p value of association
tests for about 2 million SNPs with CWP in the stage 1 meta-analysis. SNPs are plotted on the x-axis according to their position on each
chromosome. On the y-axis, the association p values with CWP are shown (as −log 10 p values). The grey solid horizontal line represents the p
value threshold of 5×10−8 (genome-wide signiﬁcance). The grey dashed horizontal line represents the p value threshold of 1×10−5 (the level for
suggestive evidence): SNPs in loci reaching 1×10−5 were tested for replication. (B) Quantile–quantile (QQ) plot of SNPs. The blue area represents
the 95% CI around the test statistics. A QQ plot compares the additive model statistics to those expected under the null distribution using ﬁxed
effects for all analysed HapMAP CEU imputed SNPs passing quality control criteria. This ﬁgure is only reproduced in colour in the online version.
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stage 1 meta-analysis. We identiﬁed a total of 44 genes, of
which 136 SNPs had been reported at least twice with any
pain phenotype (excluding facial pain, migraine, postoperative
pain and response to drug therapy), and we examined the asso-
ciation of these 136 SNPs with CWP in the GWAS stage 1
meta-analysis. Out of 136 candidate SNPs, we were able to
check 92 common SNPs (MAF>5%) in 65 independent genetic
loci (see supplementary table S10). Five SNPs had a too low
MAF (<=5%) and 39 SNPs were not genotyped or imputed in
our meta-analysis. None of the earlier reported SNPs passed the
signiﬁcance threshold (p<8×10−4). Interestingly, the strongest
associated SNPs are located in three genes that have been
reported to be associated with pain phenotypes most fre-
quently: COMT, GCH1 (GTP cyclo-hydrolase 1) and OPRM1
(mu opioid receptor). The effects of the SNPs in GCH1 are in
the same direction as reported earlier60–62: individuals having
the minor allele for rs10483639, rs4411417 or rs752688 have
15% less pain than those exhibiting the common alleles. The
effect of the SNP rs599548 in OPRM1 is also in the same direc-
tion as reported earlier63: those having the minor allele for
rs599548 have 19% more pain than those exhibiting the major
allele. The two COMT SNPs are in weak LD with the well-
known amino acid changing variant rs4860, but previously
have not been reported to be signiﬁcantly associated with
pain.23 64 We have found a protective effect for the minor allele
of rs2020917 (those having a minor allele have 15% less pain)
and an adverse effect for the minor allele of rs5993883: those
having the minor allele of rs5993883 have 14% more pain.
DISCUSSION
In this study, we identiﬁed a genetic variant near CCT5 and
FAM173B to be associated with CWP. Chronic pain coincided
with higher RNA expression of Cct5 and Fam173b in the
lumbar spinal cord of mouse models of inﬂammatory pain.
This ﬁnding indicates that both genes in the 5p15.2 region are
regulated in the context of inﬂammatory pain.
Interestingly, Bouhouche et al65 reported a human pedigree in
which a CCT5 mutation caused hereditary sensory neuropathy
(Online Mendelian Inheritance in Man (OMIM) ID=610150), a
syndrome characterised by a sensory deﬁcit in the distal portion
of the lower extremities, chronic perforating ulcerations of the
feet and progressive destruction of underlying bones. Symptoms
can include pain and numbness, tingling in the hands, legs or
feet, and extreme sensitivity to touch. CCT5 is a subunit of the
chaperonin containing t-complex polypeptide 1 (TCP-1) which
assists in protein folding and assembly in the brain.66 CCT5
interacts with the serine/threonine-protein phosphatase 4 cata-
lytic subunit PP4C.67–69 Zhang et al70 conﬁrmed that protein
phosphates like PPP4C may have a regulatory effect on the
central sensitisation of nociceptive transmission in the spinal
cord. Interestingly, sensitisation is thought to contribute to
chronic inﬂammatory pain.71 Since the function of the FAM173B
gene is not yet known, it is difﬁcult to postulate the mechanism
by which this gene could inﬂuence CWP. Further research into
the genes in this locus is needed to ascertain whether either or
both CCT5 and FAM173B are driving the observed association.
By combining the effects across the different stage 2 studies,
moderate heterogeneity was observed in the meta-analysis.
This heterogeneity might be caused by different pain assess-
ment methods used by the stage 2 cohorts. In particular, four
cohorts asked the participants about joint pain speciﬁcally,
while the other ﬁve also included non-joint pain. When the
non-joint pain phenotype were excluded, the heterogeneity
across the cohorts reduced to 0% and the overall p value for
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rs13361160 now reached genome-wide signiﬁcance by combin-
ing the stage 1 and stage 2 effects. This might suggest that
indeed phenotype heterogeneity was introduced by including
non-joint pain. In general, it is anticipated that pain is a very
complex trait, with different aetiological pathways introducing
phenotypic heterogeneity.
A limitation of our study is that we were not able to
examine possible phenotype subgroups, such as individuals
with RA, a chronic systemic inﬂammatory disorder that princi-
pally affects the synovial joints. Stratifying these groups of
individuals might serve to increase power to ﬁnd genetic loci.
We here decided to analyse all CWP cases together, based on
the hypothesis that several discrete stimuli need to initiate
CWP via a common ﬁnal pathway that involves the generation
of a central pain state through the sensitisation of second order
spinal neurons. In addition, the prevalence of RA is very low
(about 0.5–1%),72 and the earlier deﬁned GWAS hits for RA (ie,
the HLA locus)73 were not in our top list. So, we assume the
results were not dominated by this small number of individuals
with RA.
It would be helpful to dissect the phenotype of pain into quan-
titative sub-phenotypes, for example by measuring pain sensitiv-
ity and pain thresholds for temperature or pressure,74 or by
examining functional MRIs.75 The use of quantitative and
possibly more objective pain measurements in response to painful
stimuli (rather than reported pain) will be of pivotal importance
for future pain research. Because we have focused on the clinical
pain deﬁnition using questionnaires and pain homunculus, we
accept that we may have missed true pain susceptibility alleles.
However, this study represents the largest genome-wide
meta-analysis looking into the genetics of human CWP to date.
The experiments in two independent mouse models of chronic
inﬂammatory pain showed that the expression of Cct5 and
Fam173b was higher in the lumbar spinal cord of mice with
chronic inﬂammatory pain but not in DRG. In the spinal cord,
the expression proﬁles of both genes were up-regulated in response
to two different inducers of inﬂammatory pain. These ﬁndings
indicate that both genes in the 5p15.2 region are co-regulated in
the spinal cord during inﬂammation-induced pain in both inde-
pendent pain models, thereby possibly contributing to the neuro-
biology of pain. In the lumbar DRG, containing the cell bodies of
the primary sensory neurons that detect pain signals from the
hind paws, Cct5 and Fam173b gene expression levels did not
change by inﬂammation. Because of these complementary results
from the two independent tissues (spinal cord and DRG), we
hypothesise that the 5p15.2 region is likely to play a role in spinal
central pain processing and not in regulating primary sensory
neuron responses.
Figure 3 Forest plot of the association of rs13361160 SNP with chronic widespread pain (CWP). Study speciﬁc estimates and summary
association between rs13361160 and CWP are shown. This ﬁgure is only reproduced in colour in the online version.
Table 3 Top hit association results
Type of analysis Stage 1 Stage 2 Stage 1 and 2 (combined)
SNP tested Adjustments OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
rs13361160 Age, BMI, and 4 PCs 1.30 (1.19 to 1.42) 1.18×10−8 1.06 (0.98 to 1.16) 0.16 1.17 (1.10 to 1.24) 4.67×10−7
(minor allele=C, other allele=T,
MAF=43.5%)
Sensitivity analysis; joint pain only
rs13361160 Age, BMI, and 4 PCs 1.30 (1.19 to 1.42) 1.18×10−8 1.10 (0.97 to 1.25) 0.15 1.23 (1.14 to 1.32) 3.43×10−8
(minor allele=C, other allele=T,
MAF=43.5%)
In both analyses the effect estimates of the models refer to the minor allele (=effect allele).
BMI, body mass index; MAF, minor allele frequency.
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In the study of candidate genes previously reported to be
associated with a pain phenotype, we showed that none of
the 92 studied variants were signiﬁcantly associated with
CWP in our GWAS meta-analysis. This can be explained by
the fact that many of the previous reported loci were studied
in relative modest sample sizes and in a large variety of pain
phenotypes.76 Power calculations show that we had approxi-
mately 80% power to detect an OR as low as 1.22 for SNPs
with an allele frequency of 20% or higher. So, even in this
large meta-analysis, power was still modest to detect small
ORs and we therefore cannot exclude smaller effect sizes of
the tested variants, resulting in lack of reproducibility.77 This
lack of reproducibility of SNPs in candidate genes in large
GWAS meta-analyses has been shown before for other pheno-
types such as bone mineral density (BMD).78 It is interesting
to note that among the candidate SNPs, the strongest asso-
ciated ones were located in the three most studied pain genes,
COMT, GCH1 and OPRM1. The directions of the effects of
these SNPs were the same as reported earlier, which would
support true associations.
In conclusion, our study reports a GWAS meta-analysis on
CWP. We identiﬁed the genetic variant rs13361160 at the
5p15.2 locus, located 81 kb upstream of the CCT5 gene and
57 kb downstream of the FAM173B gene, to be associated with
CWP. We showed an increase in expression levels of Cct5 and
Fam173b in the spinal cord of inﬂammatory pain models of
Figure 5 Quantitative PCR analysis of gene expression levels in the lumbar (L2–L5) spinal cord (A) and the dorsal root ganglions (DRG) (B) of mice
after intraplantar saline (n=3), carrageenan (n=4), and Complete Freund’s Adjuvant (CFA) (n=4) injection. Spinal cord and DRG were collected and
analysed for RNA levels of Cct5 and Fam173b. Data were normalised for Gapdh and β-actin (housekeeping genes) expression. Data are expressed as
mean±SEM, *=p<0.05.
Figure 4 Regional plot of locus 5p15.2. On the x-axis, SNPs are plotted according to their position in a 400-kb window around rs13361160. On the
y-axis, the association p values with chronic widespread pain are shown (as −log 10 p values). The purple diamond highlights the most signiﬁcant
SNP rs13361160. Blue peaks indicate recombination sites, and the SNPs surrounding the most signiﬁcant SNP are colour coded to identify their
strength of linkage disequilibrium with the most signiﬁcant SNP (pairwise r2 values of the HapMap CEU samples). Genes and the direction of
transcription are shown at the bottom of the plot. This ﬁgure is only reproduced in colour in the online version.
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mice, and since these genes both seem to inﬂuence the central
mechanism of sensitisation, they may represent a novel
pathway involved in pain sensation.
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